APO Research
Talk to an analyst

APO RESEARCH · REPORT

Fabrazyme (agalsidase beta)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Fabrazyme (agalsidase beta) Market Outlook and Growth Opportunities 2026

20 December 2025197 pages

Choose your research edition.

Industry ResearchFabrazyme (agalsidase beta) Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Fabrazyme (agalsidase beta) Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal Fabrazyme (agalsidase beta) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fabrazyme (agalsidase beta) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Fabrazyme (agalsidase beta) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Fabrazyme (agalsidase beta) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Fabrazyme (agalsidase beta) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Fabrazyme (agalsidase beta) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Fabrazyme (agalsidase beta) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Fabrazyme (agalsidase beta) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Fabrazyme (agalsidase beta) market include Genzyme Corporation. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Fabrazyme (agalsidase beta) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Fabrazyme (agalsidase beta) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Fabrazyme (agalsidase beta) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Fabrazyme (agalsidase beta) market size, projected growth trends, production technologies, key applications, and end-use industries.

Fabrazyme (agalsidase beta) Segment by Company

Genzyme Corporation

Fabrazyme (agalsidase beta) Segment by Type

5mg/vial

35mg/vial

Fabrazyme (agalsidase beta) Segment by Application

Hospital

Drug store

Fabrazyme (agalsidase beta) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Fabrazyme (agalsidase beta) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Fabrazyme (agalsidase beta) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Fabrazyme (agalsidase beta) significant trends, drivers, influence factors in global and regions.

6. To analyze Fabrazyme (agalsidase beta) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fabrazyme (agalsidase beta) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fabrazyme (agalsidase beta) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fabrazyme (agalsidase beta).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Fabrazyme (agalsidase beta) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Fabrazyme (agalsidase beta) industry.

Chapter 3: Detailed analysis of Fabrazyme (agalsidase beta) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Fabrazyme (agalsidase beta) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Fabrazyme (agalsidase beta) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Fabrazyme (agalsidase beta) Industry Trends Table 2. Fabrazyme (agalsidase beta) Industry Drivers Table 3. Fabrazyme (agalsidase beta) Industry Opportunities and Challenges Table 4. Fabrazyme (agalsidase beta) Industry Restraints Table 5. Global Fabrazyme (agalsidase beta) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Fabrazyme (agalsidase beta) Revenue Share by Company (2021-2026) Table 7. Global Fabrazyme (agalsidase beta) Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Fabrazyme (agalsidase beta) Sales Volume Share by Company (2021-2026) Table 9. Global Fabrazyme (agalsidase beta) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Fabrazyme (agalsidase beta) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Fabrazyme (agalsidase beta) Key Company Manufacturing Base & Headquarters Table 12. Global Fabrazyme (agalsidase beta) Company, Product Type & Application Table 13. Global Fabrazyme (agalsidase beta) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Fabrazyme (agalsidase beta) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5mg/vial Table 18. Significant Companies of 35mg/vial Table 19. Global Fabrazyme (agalsidase beta) Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global Fabrazyme (agalsidase beta) Sales Volume by Type (2021-2026) & (W Units) Table 21. Global Fabrazyme (agalsidase beta) Sales Volume by Type (2027-2032) & (W Units) Table 22. Global Fabrazyme (agalsidase beta) Sales Volume Share by Type (2021-2026) Table 23. Global Fabrazyme (agalsidase beta) Sales Volume Share by Type (2027-2032) Table 24. Global Fabrazyme (agalsidase beta) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Fabrazyme (agalsidase beta) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Fabrazyme (agalsidase beta) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Fabrazyme (agalsidase beta) Sales Value Share by Type (2021-2026) Table 28. Global Fabrazyme (agalsidase beta) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Drug store Table 31. Global Fabrazyme (agalsidase beta) Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global Fabrazyme (agalsidase beta) Sales Volume by Application (2021-2026) & (W Units) Table 33. Global Fabrazyme (agalsidase beta) Sales Volume by Application (2027-2032) & (W Units) Table 34. Global Fabrazyme (agalsidase beta) Sales Volume Share by Application (2021-2026) Table 35. Global Fabrazyme (agalsidase beta) Sales Volume Share by Application (2027-2032) Table 36. Global Fabrazyme (agalsidase beta) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Fabrazyme (agalsidase beta) Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Fabrazyme (agalsidase beta) Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Fabrazyme (agalsidase beta) Sales Value Share by Application (2021-2026) Table 40. Global Fabrazyme (agalsidase beta) Sales Value Share by Application (2027-2032) Table 41. Global Fabrazyme (agalsidase beta) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global Fabrazyme (agalsidase beta) Sales by Region (2021-2026) & (W Units) Table 43. Global Fabrazyme (agalsidase beta) Sales Market Share by Region (2021-2026) Table 44. Global Fabrazyme (agalsidase beta) Sales by Region (2027-2032) & (W Units) Table 45. Global Fabrazyme (agalsidase beta) Sales Market Share by Region (2027-2032) Table 46. Global Fabrazyme (agalsidase beta) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Fabrazyme (agalsidase beta) Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Fabrazyme (agalsidase beta) Sales Value Share by Region (2021-2026) Table 49. Global Fabrazyme (agalsidase beta) Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Fabrazyme (agalsidase beta) Sales Value Share by Region (2027-2032) Table 51. Global Fabrazyme (agalsidase beta) Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Fabrazyme (agalsidase beta) Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Fabrazyme (agalsidase beta) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Global Fabrazyme (agalsidase beta) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Fabrazyme (agalsidase beta) Sales by Country (2021-2026) & (W Units) Table 56. Global Fabrazyme (agalsidase beta) Sales Market Share by Country (2021-2026) Table 57. Global Fabrazyme (agalsidase beta) Sales by Country (2027-2032) & (W Units) Table 58. Global Fabrazyme (agalsidase beta) Sales Market Share by Country (2027-2032) Table 59. Global Fabrazyme (agalsidase beta) Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Fabrazyme (agalsidase beta) Sales Value Market Share by Country (2021-2026) Table 61. Global Fabrazyme (agalsidase beta) Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Fabrazyme (agalsidase beta) Sales Value Market Share by Country (2027-2032) Table 63. Genzyme Corporation Company Information Table 64. Genzyme Corporation Business Overview Table 65. Genzyme Corporation Fabrazyme (agalsidase beta) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Genzyme Corporation Fabrazyme (agalsidase beta) Product Portfolio Table 67. Genzyme Corporation Recent Development Table 68. Key Raw Materials Table 69. Raw Materials Key Suppliers Table 70. Fabrazyme (agalsidase beta) Distributors List Table 71. Fabrazyme (agalsidase beta) Customers List Table 72. Research Programs/Design for This Report Table 73. Authors List of This Report Table 74. Secondary Sources Table 75. Primary Sources List of Figures Figure 1. Fabrazyme (agalsidase beta) Product Image Figure 2. Global Fabrazyme (agalsidase beta) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fabrazyme (agalsidase beta) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Fabrazyme (agalsidase beta) Sales (2021-2032) & (W Units) Figure 5. Global Fabrazyme (agalsidase beta) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Fabrazyme (agalsidase beta) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5mg/vial Image Figure 10. 35mg/vial Image Figure 11. Global Fabrazyme (agalsidase beta) Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global Fabrazyme (agalsidase beta) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Fabrazyme (agalsidase beta) Sales Volume Share by Type (2021-2032) Figure 14. Global Fabrazyme (agalsidase beta) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Fabrazyme (agalsidase beta) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Fabrazyme (agalsidase beta) Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drug store Image Figure 19. Global Fabrazyme (agalsidase beta) Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Fabrazyme (agalsidase beta) Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Fabrazyme (agalsidase beta) Sales Volume Share by Application (2021-2032) Figure 22. Global Fabrazyme (agalsidase beta) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Fabrazyme (agalsidase beta) Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Fabrazyme (agalsidase beta) Sales Value Share by Application (2021-2032) Figure 25. Global Fabrazyme (agalsidase beta) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 26. Global Fabrazyme (agalsidase beta) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Fabrazyme (agalsidase beta) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Fabrazyme (agalsidase beta) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Fabrazyme (agalsidase beta) Sales Value (2021-2032) & (US$ Million) Figure 30. North America Fabrazyme (agalsidase beta) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Fabrazyme (agalsidase beta) Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Fabrazyme (agalsidase beta) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Fabrazyme (agalsidase beta) Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Fabrazyme (agalsidase beta) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Fabrazyme (agalsidase beta) Sales Value (2021-2032) & (US$ Million) Figure 36. South America Fabrazyme (agalsidase beta) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Fabrazyme (agalsidase beta) Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Fabrazyme (agalsidase beta) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Fabrazyme (agalsidase beta) Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Fabrazyme (agalsidase beta) Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 5mg/vial
  • 35mg/vial
Applications
  • Hospital
  • Drug store
Companies covered
  • Genzyme Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Fabrazyme (agalsidase beta) Sales Value (2021-2032)
  4. 1.2.2 Global Fabrazyme (agalsidase beta) Sales Volume (2021-2032)
  5. 1.2.3 Global Fabrazyme (agalsidase beta) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Fabrazyme (agalsidase beta) Market Dynamics
  1. 2.1 Fabrazyme (agalsidase beta) Industry Trends
  2. 2.2 Fabrazyme (agalsidase beta) Industry Drivers
  3. 2.3 Fabrazyme (agalsidase beta) Industry Opportunities and Challenges
  4. 2.4 Fabrazyme (agalsidase beta) Industry Restraints
3 Fabrazyme (agalsidase beta) Market by Company
  1. 3.1 Global Fabrazyme (agalsidase beta) Company Revenue Ranking in 2025
  2. 3.2 Global Fabrazyme (agalsidase beta) Revenue by Company (2021-2026)
  3. 3.3 Global Fabrazyme (agalsidase beta) Sales Volume by Company (2021-2026)
  4. 3.4 Global Fabrazyme (agalsidase beta) Average Price by Company (2021-2026)
  5. 3.5 Global Fabrazyme (agalsidase beta) Company Ranking (2024-2026)
  6. 3.6 Global Fabrazyme (agalsidase beta) Company Manufacturing Base and Headquarters
  7. 3.7 Global Fabrazyme (agalsidase beta) Company Product Type and Application
  8. 3.8 Global Fabrazyme (agalsidase beta) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Fabrazyme (agalsidase beta) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Fabrazyme (agalsidase beta) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Fabrazyme (agalsidase beta) Market by Type
  1. 4.1 Fabrazyme (agalsidase beta) Type Introduction
  2. 4.1.1 5mg/vial
  3. 4.1.2 35mg/vial
  4. 4.2 Global Fabrazyme (agalsidase beta) Sales Volume by Type
  5. 4.2.1 Global Fabrazyme (agalsidase beta) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Fabrazyme (agalsidase beta) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Fabrazyme (agalsidase beta) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Fabrazyme (agalsidase beta) Sales Value by Type
  9. 4.3.1 Global Fabrazyme (agalsidase beta) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Fabrazyme (agalsidase beta) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Fabrazyme (agalsidase beta) Sales Value Share by Type (2021-2032)
5 Fabrazyme (agalsidase beta) Market by Application
  1. 5.1 Fabrazyme (agalsidase beta) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug store
  4. 5.2 Global Fabrazyme (agalsidase beta) Sales Volume by Application
  5. 5.2.1 Global Fabrazyme (agalsidase beta) Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Fabrazyme (agalsidase beta) Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Fabrazyme (agalsidase beta) Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Fabrazyme (agalsidase beta) Sales Value by Application
  9. 5.3.1 Global Fabrazyme (agalsidase beta) Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Fabrazyme (agalsidase beta) Sales Value by Application (2021-2032)
  11. 5.3.3 Global Fabrazyme (agalsidase beta) Sales Value Share by Application (2021-2032)
6 Fabrazyme (agalsidase beta) Regional Sales and Value Analysis
  1. 6.1 Global Fabrazyme (agalsidase beta) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Fabrazyme (agalsidase beta) Sales by Region (2021-2032)
  3. 6.2.1 Global Fabrazyme (agalsidase beta) Sales by Region: 2021-2026
  4. 6.2.2 Global Fabrazyme (agalsidase beta) Sales by Region (2027-2032)
  5. 6.3 Global Fabrazyme (agalsidase beta) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Fabrazyme (agalsidase beta) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Fabrazyme (agalsidase beta) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Fabrazyme (agalsidase beta) Sales Value by Region (2027-2032)
  9. 6.5 Global Fabrazyme (agalsidase beta) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Fabrazyme (agalsidase beta) Sales Value (2021-2032)
  12. 6.6.2 North America Fabrazyme (agalsidase beta) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Fabrazyme (agalsidase beta) Sales Value (2021-2032)
  15. 6.7.2 Europe Fabrazyme (agalsidase beta) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Fabrazyme (agalsidase beta) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Fabrazyme (agalsidase beta) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Fabrazyme (agalsidase beta) Sales Value (2021-2032)
  21. 6.9.2 South America Fabrazyme (agalsidase beta) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Fabrazyme (agalsidase beta) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Fabrazyme (agalsidase beta) Sales Value Share by Country, 2025 VS 2032
7 Fabrazyme (agalsidase beta) Country-level Sales and Value Analysis
  1. 7.1 Global Fabrazyme (agalsidase beta) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Fabrazyme (agalsidase beta) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Fabrazyme (agalsidase beta) Sales by Country (2021-2032)
  4. 7.3.1 Global Fabrazyme (agalsidase beta) Sales by Country (2021-2026)
  5. 7.3.2 Global Fabrazyme (agalsidase beta) Sales by Country (2027-2032)
  6. 7.4 Global Fabrazyme (agalsidase beta) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Fabrazyme (agalsidase beta) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Fabrazyme (agalsidase beta) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Fabrazyme (agalsidase beta) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Fabrazyme (agalsidase beta) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Fabrazyme (agalsidase beta) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Genzyme Corporation
  2. 8.1.1 Genzyme Corporation Company Information
  3. 8.1.2 Genzyme Corporation Business Overview
  4. 8.1.3 Genzyme Corporation Fabrazyme (agalsidase beta) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Genzyme Corporation Fabrazyme (agalsidase beta) Product Portfolio
  6. 8.1.5 Genzyme Corporation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Fabrazyme (agalsidase beta) Value Chain Analysis
  2. 9.1.1 Fabrazyme (agalsidase beta) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Fabrazyme (agalsidase beta) Sales Mode & Process
  6. 9.2 Fabrazyme (agalsidase beta) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Fabrazyme (agalsidase beta) Distributors
  9. 9.2.3 Fabrazyme (agalsidase beta) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst